Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: J Pharm Biomed Anal. 2011 Mar 5;55(3):487–493. doi: 10.1016/j.jpba.2011.01.040

Figure 2.

Figure 2

Representative chromatograms of blank human plasma to assess potential interfering peaks at the retention times and MRM transitions for (A) midazolam, (B) midazolam d4, (C) alfentanil, and (D) alfentanil d5.